Use code “SPRING15” to get 15% off your first order! / FREE Hospira with orders over $300
NAD+ levels decline by up to 50% between ages 40 and 60, correlating with mitochondrial dysfunction, DNA damage accumulation, and metabolic decline. This article examines the science behind NAD+ restoration as a longevity strategy.

Nicotinamide adenine dinucleotide (NAD+) occupies a unique position in biochemistry. Present in every living cell, this coenzyme participates in over 500 enzymatic reactions and serves as the essential substrate for some of the most consequential enzymes in human biology — the sirtuins, PARPs, and CD38. The discovery that NAD+ levels decline precipitously with age, and that this decline drives multiple hallmarks of aging, has placed NAD+ restoration at the center of modern longevity research.
This article examines the biology of NAD+ decline, its consequences for cellular function, and the current evidence supporting NAD+ restoration as a strategy for extending healthspan.
While NAD+ is classically known for its role in redox metabolism — shuttling electrons in glycolysis, the TCA cycle, and oxidative phosphorylation — its significance extends far beyond energy production. NAD+ serves as a consumed substrate for three major enzyme families:
The critical insight is that these enzymes consume NAD+ — they don't merely use it as a cofactor. This creates a direct competition for a finite NAD+ pool, and as demand increases with age (due to accumulated DNA damage and chronic inflammation), the supply diminishes. The result is a vicious cycle of declining NAD+, impaired repair, and accelerating damage.
Multiple studies have quantified the age-related decline in NAD+. Tissue-specific measurements in mice show a 30-50% reduction in NAD+ levels by middle age, with similar trends observed in human cohorts. The decline is not uniform across tissues: metabolically active organs like the liver, brain, and skeletal muscle show the most pronounced depletion.
The primary driver of this decline appears to be CD38, whose expression increases with age and chronic inflammation. Camacho-Pereira et al. (2016) demonstrated that CD38 knockout mice maintain youthful NAD+ levels into old age and are protected from age-related metabolic dysfunction. This finding shifted the field's focus from NAD+ synthesis to NAD+ preservation, and identified CD38 inhibition as a potential complementary strategy to NAD+ supplementation.
The sirtuin family represents the most direct link between NAD+ levels and aging outcomes. SIRT1, the most studied member, deacetylates key transcription factors including PGC-1α (mitochondrial biogenesis), FOXO3 (stress resistance and autophagy), and NF-κB (inflammation). When NAD+ levels are sufficient, SIRT1 activity maintains these pathways in a pro-survival, anti-inflammatory state. When NAD+ declines, sirtuin activity falls and inflammatory, pro-aging programs dominate.
"NAD+ is not merely a metabolic cofactor — it is a signaling molecule that connects cellular energy status to the epigenetic regulation of aging. Its decline is not a consequence of aging; it is a cause." — Imai & Guarente, Trends in Cell Biology, 2014
NAD+ is essential for mitochondrial function at multiple levels. In the electron transport chain, NAD+ accepts electrons from metabolic substrates to drive ATP synthesis. But its role extends to mitochondrial quality control: NAD+-dependent SIRT3 deacetylates and activates key mitochondrial enzymes, while SIRT1 promotes mitochondrial biogenesis through PGC-1α activation.
The decline in NAD+ creates a characteristic "pseudohypoxic" state — first described by Gomes et al. (2013) — where mitochondria function as though oxygen supply is limited, even under normoxic conditions. This pseudo-hypoxia disrupts the nuclear-mitochondrial communication axis and contributes to the metabolic inflexibility that characterizes aged tissue.
The relationship between NAD+ and genome stability is mediated primarily through PARP enzymes. PARP1, the most active family member, detects single-strand DNA breaks and initiates repair by consuming NAD+ to build poly-ADP-ribose chains at damage sites. Under conditions of extensive DNA damage — as occurs with aging, UV exposure, or genotoxic stress — PARP activation can deplete NAD+ pools, simultaneously compromising sirtuin activity and leaving the cell in a repair-deficient state.
This NAD+ competition between PARPs and sirtuins has been termed the "NAD+ metabolite crisis" and represents a key vulnerability point in aging biology. Restoring NAD+ levels ensures both DNA repair and sirtuin-mediated gene regulation can operate simultaneously.
Current NAD+ restoration approaches include direct NAD+ supplementation and administration of NAD+ precursors (NMN and NR) that are enzymatically converted to NAD+ intracellularly. Each approach has distinct pharmacokinetics and tissue distribution profiles, and ongoing clinical trials are establishing optimal dosing strategies for different health outcomes.
Combination strategies pairing NAD+ with complementary compounds — particularly those targeting AMPK activation (such as MOTS-c) — may address cellular energy and repair from synergistic angles. The convergence of NAD+/sirtuin and AMPK pathways on mitochondrial biogenesis and metabolic flexibility provides a strong mechanistic rationale for multi-target approaches.
The NAD+ story is, in many ways, the story of aging itself. A single molecule connects energy production, DNA repair, gene expression, and inflammation — the fundamental processes that determine whether a cell ages gracefully or deteriorates. The accumulating evidence that NAD+ restoration can meaningfully reverse aspects of cellular aging represents one of the most actionable findings in modern gerontology. As clinical data matures, NAD+ supplementation may become a cornerstone of evidence-based longevity strategies.
Continue exploring
Browse All Research